BioSante (BPAX) Rips Higher Following Strong GVAX Phase Ib Data
Tweet
Share
E-mailGet Alerts BPAX Hot Sheet
Join SI Premium – FREE
BioSante Pharmaceuticals, Inc. (Nasdaq: BPAX) is ripping higher Monday morning following the release of positive data from the Phase Ib clinical study of its GVAX Pancreas cancer vaccine. According to BioSante, GVAX "increased the median survival of pancreatic cancer patients with previously treated, locally advanced or metastatic pancreatic adenocarcinoma (PDA), from 3.3 months when treated with ipilimumab (IPI; Yervoy; BMS), to 5.5 months on the combination of IPI plus GVAX Pancreas, an increase of more than 60 percent."
Shares are up over 15 percent early. For more color, click here.
Shares are up over 15 percent early. For more color, click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JCap cautious on Opendoor: 'buys and flips houses for a profit but makes no profit'
- Trump: Negotiators Can Continue W/ Iran, Will See What Happens
- Trump Did Not Repeat Termination Of Interim Deal With Iran During Nato Summit, Source Familiar With The Talks Says - Reuters
Create E-mail Alert Related Categories
FDA, Insiders' Blog, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
